RecruitingNot ApplicableNCT05823272
ONS in Gastric Cancer After Total Gastrectomy
Effect of Oral Nutritional Supplement on Nutritional Status and Clinical Outcome in Gastric Cancer Patients After Total Gastrectomy
Sponsor
Jinling Hospital, China
Enrollment
60 participants
Start Date
Mar 22, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Gastric cancer patients after total gastrectomy will be randomized to oral nutritional supplement group or control group at discharge. Patients will receive 6 months of oral nutritional supplement or normal diet after discharge. The primary and secondary outcomes will be collected.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria5
- Informed consent of patients or their legal representatives to participate in this study
- consecutive adult (18-80 years) patients underwent radical gastrectomy (total gastrectomy)
- nutrition Risk Screening (NRS) 2002≥3 at discharge
- eastern Cooperative Oncology Group (ECOG) score of 0-2 at discharge
- normal liver and kidney function
Exclusion Criteria9
- unable to oral or consume ONS
- allergy to any ingredient in the oral nutrition powder
- pregnancy
- palliative surgery or gastric stump cancer
- congenital acquired immune deficiency disease
- severe liver and kidney diseases including active hepatitis, cirrhosis, and uremia diabetes has developed complications or uncontrolled by medications
- motor system diseases cannot complete grip strength measurement and 5-time chair stand test
- have cognitive impairment, unable to complete the relevant questionnaires
- expected to require tube feeding after discharge from the hospital
Interventions
OTHERONS
oral nutritional supplement
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05823272
Related Trials
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
NCT051871821 location
Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
NCT072774391 location
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT0570222944 locations
Study for AZD4360 in Participants With Advanced Solid Tumours
NCT0692192817 locations
Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Gastric Cancers in Algeria
NCT074811102 locations